Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.7% Higher – Should You Buy?

by · The Cerbat Gem

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares shot up 6.7% during mid-day trading on Friday . The company traded as high as $7.05 and last traded at $7.03. 1,938,599 shares changed hands during trading, a decline of 68% from the average session volume of 6,136,487 shares. The stock had previously closed at $6.59.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on RXRX. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, November 20th. Leerink Partners lowered their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group decreased their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $9.25.

Check Out Our Latest Analysis on Recursion Pharmaceuticals

Recursion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market capitalization of $2.24 billion, a P/E ratio of -5.28 and a beta of 0.85. The stock’s fifty day simple moving average is $6.59 and its 200 day simple moving average is $7.35.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.43) EPS. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at $3,647,966. This trade represents a 1.14 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Christopher Gibson sold 20,000 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total value of $123,200.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,697,960.96. This trade represents a 2.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 134,235 shares of company stock worth $895,538 in the last quarter. Corporate insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC purchased a new position in shares of Recursion Pharmaceuticals during the 3rd quarter worth $25,000. Farther Finance Advisors LLC boosted its stake in shares of Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after buying an additional 4,091 shares during the period. GAMMA Investing LLC raised its position in shares of Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after acquiring an additional 6,036 shares in the last quarter. Amalgamated Bank raised its position in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares in the last quarter. Finally, KBC Group NV raised its position in shares of Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after acquiring an additional 3,377 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

See Also